Boston Elite
Michael Cohen co-leads the life sciences group emerging growth companies and venture capital group at Brown Rudnick LLP. Cohen specialises in representing both start-ups and established businesses in mergers and acquisitions, joint ventures and other transactional matters, focusing his clientele within the life sciences and technology sectors. Some of Cohen’s recent clients include Aktis Oncology, Crosslink Therapuetics, MPM BioImpact and Sincere Corporations.
Legal 500 Editorial commentary
Accolades
Boston Elite
Mentions
Profile
Work Department
Life Sciences Group, Emerging Growth Companies and Venture Capital Group
Position
Partner
Career
Michael Cohen is co-practice group leader of Brown Rudnick’s Global Life Sciences Group and of the firm’s Emerging Growth Companies & Venture Capital Group. He advises on high-profile matters in the life sciences and technology sectors. Michael's clients regularly rely on him to be a true outside general counsel, ready and able to handle matters big and small as they arise.
Michael represents early stage and mid-market companies in corporate structuring, mergers and acquisitions, joint ventures and strategic alliances, financing transactions, and other general transactional matters at all stages of the corporate life cycle. Michael also advises venture, hedge, and private equity funds, universities, corporate venture groups, and portfolio companies in connection with financing transaction deal terms and stockholders' agreements, technology licensing, corporate governance and securities law compliance in connection with private offerings.
Michael also works closely with Brown Rudnick’s London office in counseling U.K. and European clients engaging in transactions involving U.S. concerns.
Content supplied by Brown Rudnick LLP
Key clients
- Aktis Oncology Crosslink Therapeutics MPM BioImpact Sincere Corporation
Work highlights
Acted as corporate and transactional counsel for Aktis Oncology in its $161 million Series A financing and its $175 million Series B financing for developing targeted radiopharmaceuticals to treat solid tumour cancers.
Represented Crosslink Therapeutics in its SAFE financing in developing ATP-assembled conditional biologics designed to treat cancer.
Represented Sincere Corporation, parent company of consumer-focused web services Punchbowl, Momento, Timehop, and Lovebird in various financings and acquisitions.